04/16/2022
In this podcast, George Bakris, MD, from the University of Chicago, talks about the renal outcomes from the Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) trial.
George Bakris, MD, is a professor of medicine and director of the American Heart Association's Comprehensive Hypertension Center at the University of Chicago Medicine in Chicago, Illinois.
Additional Resources:
- Bakris GL. Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors [published online June 28, 2019]. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2019.05.009.
- Heerspink HJL, Parving HH, Andress DL, Bakris G, et al; SONAR Committees and Investigators. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):P1937-1947. https://doi.org/10.1016/S0140-6736(19)30772-X.
- Seck T. EMPA-REG OUTCOME trial: empagliflozin reduces CV risk by 38% [podcast]. East Windsor, NJ; Cardiology Consultant: 2017. https://www.consultant360.com/content/empa-reg-outcome-trial-empagliflozin-reduces-cv-risk-38.
- Vogt C. Empagliflozin slows kidney disease in type 2 diabetes patients [published online November 2, 2017]. Consultant360. https://www.consultant360.com/exclusives/empagliflozin-slows-kidney-disease-type-2-diabetes-patients.
- Vogt C. Canagliflozin, linagliptin shown to benefit CV and renal function [published online June 13, 2019]. Consultant360. https://www.consultant360.com/exclusive/consultant360/diabetes/canagliflozin-linagliptin-shown-benefit-cv-and-renal-function.
